Minimally Invasive Robotic Surgery Systems Articles & Analysis
14 news found
Analysis provides further validation of MINIject®’s meaningful and sustained efficacy in open angle glaucoma patients No safety concerns with corneal endothelial health reported across all three trials MINIject® delivers positive, consistent results up to two-year follow-up in patients across Central and South America, Asia and Europe WAVRE, Belgium — 8 June 2022: ...
June 8.2022 - Medical Microinstruments (MMI), a robotics company dedicated to improving clinical outcomes for patients undergoing microsurgery, today announced that it will participate in "THE MINIMALLY INVASIVE ROBOTIC SURGERY SYSTEMS project (TREMIRS). ...
Gières (Grenoble), France, June 17, 2021 - eCential Robotics, a French growth company that designs, manufactures and markets the first unified 2D/3D robotic imaging and surgical navigation system for bone surgery indications, unveiled its surgical robotic arm as a world premiere at the annual meeting ...
Surgery has inherent risks, but wires and lights probably do not immediately come to mind as safety threats. Yet, in the OR, a large number of wires could contribute to falls and procedure delays, and high-heat lights could cause injuries. Lazurite Holdings LLC hopes to address these issues as well as promote efficiency with its inaugural and platform product, Arthrofree Wireless Camera System. ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle glaucoma, without concurrent cataract surgery. Up to 80% ...
DUBLIN–(BUSINESS WIRE)–Mainstay Medical Holdings plc today announced the appointment of two new independent members to the company’s board of directors, Jeffrey Dunn and Eric Major. These appointments bring Mainstay’s total board membership to seven. “We are pleased to welcome these two transformational business leaders as new independent directors on the ...
The operation aims to finance research and innovation to help the company achieve its ambition of becoming the digital surgery and robotics standard of the operating room for neuro-musculo-skeletal surgery. ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the rate of visual field loss by 47% versus cataract surgery alone. The breakthrough findings position the ...
Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, today announced that it has entered into an agreement with Glaukos Corporation to settle and dismiss all pending global litigation between them. Under the agreement’s terms, Ivantis has agreed to pay a total of ...
Gières (Grenoble), France, May 26, 2021 - eCential Robotics, a French growth company that designs and produces the only system fully unifying 2D/3D robotic imaging and surgical navigation for bone surgery indications, today announced the launch of its training Institute. ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, announced today the first-ever release of five-year follow-up data from its HORIZON pivotal trial. This significant milestone represents the longest continuous follow-up of a MIGS device pivotal trial and comes on the ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure in patients with open-angle glaucoma, is proud to be the recipient of multiple awards and recognition this year for its innovation and excellence in helping to change the standard of care for the world’s 80 million glaucoma patients, as well as its ...
Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, announced today that the American Academy of Ophthalmology (AAO) has designated the Hydrus Microstent as “Level 1, Moderate Quality, Strong Recommendation” — the highest designation of any MIGS device ...
Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, announced today the first-ever, four-year follow-up data for a MIGS device in an FDA pivotal trial. The latest findings from the HORIZON study confirm the benefits of the Hydrus Microstent seen in earlier follow-up and ...